| II-04 Khalil Ben Hassine A physiologically based pharmacokinetic modelling and “virtual twin” simulation approach for the prediction of busulfan exposure in young children undergoing hematopoietic stem cell transplantation. Wednesday 15:10-16:40 |
| II-05 Andrzej Bienczak Application of model informed drug development to pediatric program for ligelizumab in Chronic Spontaneous Urticaria Wednesday 15:10-16:40 |
| II-12 Suthunya Chupradit Population Pharmacokinetic analysis of lopinavir in children with HIV in Africa receiving the pediatric lopinavir/ritonavir pellets formulation Wednesday 15:10-16:40 |
| II-19 Aline Engbers Understanding patent ductus arteriosus closure in preterm infants by detangling the effects of patient characteristics, treatment timing and ibuprofen exposure Wednesday 15:10-16:40 |
| II-21 Klervi GOLHEN Value of literature review to inform development and use of biologics in juvenile idiopathic arthritis Wednesday 15:10-16:40 |
| II-22 Verena Gotta Characterizing associations of nocturnal glycemic control with QTc interval in children with type 1 diabetes – a model-based analysis Wednesday 15:10-16:40 |
| II-25 Paul Healy In silico evaluation of the effect of CYP2D6 and OCT1 genotype variants on the pharmacokinetics and clinical safety of tramadol in infants, children and adolescents Wednesday 15:10-16:40 |
| II-28 Zoe Kane Model based estimation of posaconazole tablet and suspension oral bioavailability using real world electronic health record (EHR) and therapeutic drug monitoring (TDM) data in children. Wednesday 15:10-16:40 |
| II-29 Wannee kantasiripitak Model-informed precision dosing during infliximab induction therapy to improve long-term deep remission rates in paediatric patients with inflammatory bowel diseases Wednesday 15:10-16:40 |
| II-50 Franziska Schädeli Stark A model-informed learn-confirm approach for balovaptan paediatric dose selection to achieve adult-equivalent drug exposure Wednesday 15:10-16:40 |
| II-58 Lufina Tsirizani A pooled pharmacokinetic analysis of rifampicin, isoniazid, and pyrazinamide in paediatric patients with tuberculosis. Wednesday 15:10-16:40 |
| II-60 Anne van Rongen Decision tables for the selection of allometric and other methods to scale adult drug clearance to children: making it as simple as possible but not simpler Wednesday 15:10-16:40 |
| II-61 Roeland Wasmann A semi-mechanistic population pharmacokinetic model of tenofovir alafenamide fumarate and tenofovir in paediatric patients living with HIV Wednesday 15:10-16:40 |
| II-62 Yunjiao Wu Maturation of formation clearance of paracetamol metabolites after intravenous paracetamol dosing in preterm neonates Wednesday 15:10-16:40 |
